Challenges in natural product-based drug discovery assisted with in silico-based methods

The application of traditional medicine by humans for the treatment of ailments as well as improving the quality of life far outdates recorded history. To date, a significant percentage of humans, especially those living in developing/underprivileged communities still rely on traditional medicine for primary healthcare needs. In silico-based methods have been shown to play a pivotal role in modern pharmaceutical drug discovery processes. The application of these methods in identifying natural product (NP)-based hits has been successful. This is very much observed in many research set-ups that use rationally in silico-based methods in combination with experimental validation techniques. The combination has rendered the use of in silico-based approaches even more popular and successful in the investigation of NPs. However, identifying and proposing novel NP-based hits for experimental validation comes with several challenges such as the availability of compounds by suppliers, the huge task of separating pure compounds from complex mixtures, the quantity of samples available from the natural source to be tested, not to mention the potential ecological impact if the natural source is exhausted. Because most peer-reviewed publications are biased towards “positive results”, these challenges are generally not discussed in publications. In this review, we highlight and discuss these challenges. The idea is to give interested scientists in this field of research an idea of what they can come across or should be expecting as well as prompting them on how to avoid or fix these issues.

[1]  Zhuang Yang,et al.  From natural products to HDAC inhibitors: An overview of drug discovery and design strategy. , 2021, Bioorganic & medicinal chemistry.

[2]  Roger G. Linington,et al.  The Natural Products Atlas 2.0: a database of microbially-derived natural products , 2021, Nucleic Acids Res..

[3]  C. Benítez-Cardoza,et al.  Identifying compounds that prevent the binding of the SARS-CoV-2 S-protein to ACE2 , 2021, Computers in Biology and Medicine.

[4]  José L. Medina-Franco,et al.  Grand Challenges of Computer-Aided Drug Design: The Road Ahead , 2021, Frontiers in Drug Discovery.

[5]  M. Kumar,et al.  Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis , 2021, Computers in Biology and Medicine.

[6]  J. Lameira,et al.  Applications of Virtual Screening in Bioprospecting: Facts, Shifts, and Perspectives to Explore the Chemo-Structural Diversity of Natural Products , 2021, Frontiers in Chemistry.

[7]  Aiping Lu,et al.  ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties , 2021, Nucleic Acids Res..

[8]  D. Menche Design and Synthesis of Simplified Polyketide Analogs: New Modalities beyond the Rule of 5 , 2021, ChemMedChem.

[9]  R. Bauer,et al.  Natural products in drug discovery: advances and opportunities , 2021, Nature Reviews Drug Discovery.

[10]  W. Sippl,et al.  Strategies To Design Selective Histone Deacetylase Inhibitors , 2021, ChemMedChem.

[11]  José L. Medina-Franco,et al.  Informatics for Chemistry, Biology, and Biomedical Sciences. , 2020, Journal of chemical information and modeling.

[12]  José L Medina-Franco,et al.  Cheminformatics to Characterize Pharmacologically Active Natural Products , 2020, Biomolecules.

[13]  Yurii S Moroz,et al.  ZINC20 - A Free Ultralarge-Scale Chemical Database for Ligand Discovery , 2020, J. Chem. Inf. Model..

[14]  Stefan Günther,et al.  StreptomeDB 3.0: an updated compendium of streptomycetes natural products , 2020, Nucleic Acids Res..

[15]  Kiran K. Telukunta,et al.  Pharmacoinformatic Investigation of Medicinal Plants from East Africa , 2020, Molecular informatics.

[16]  Tian-yi Yuan,et al.  The strategies and techniques of drug discovery from natural products. , 2020, Pharmacology & therapeutics.

[17]  K. To,et al.  Detection of SARS-CoV-2 in conjunctival secretions from patients without ocular symptoms , 2020, Infection.

[18]  Mehmet Aziz Yirik,et al.  COCONUT online: Collection of Open Natural Products database , 2020, Journal of Cheminformatics.

[19]  B. Coutard,et al.  Drugs against SARS‐CoV‐2: What do we know about their mode of action? , 2020, Reviews in medical virology.

[20]  Stefan Günther,et al.  Exploring Cocrystallized Aromatic Cage Binders to Target Histone Methylation Reader Proteins , 2020, J. Chem. Inf. Model..

[21]  M. Raad,et al.  COVID-19: A Multidisciplinary Review , 2020, Frontiers in Public Health.

[22]  Ya Chen,et al.  Cheminformatics in Natural Product‐based Drug Discovery , 2020, Molecular informatics.

[23]  J. Medina-Franco,et al.  In Silico ADME/Tox Profiling of Natural Products: A Focus on BIOFACQUIM , 2020, ACS omega.

[24]  I. Tietjen,et al.  Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening , 2020, Frontiers in Pharmacology.

[25]  L. Menghini,et al.  Implementation of Nagoya Protocol on Access and benefit-sharing in Peru: Implications for researchers. , 2020, Journal of ethnopharmacology.

[26]  F. Svensson,et al.  Computational Chemistry on a Budget - Supporting Drug Discovery with Limited Resources. , 2020, Journal of medicinal chemistry.

[27]  Z. Dai,et al.  Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis , 2020, Journal of Clinical Virology.

[28]  Maria Sorokina,et al.  Review on natural products databases: where to find data in 2020 , 2020, Journal of Cheminformatics.

[29]  Heng Li,et al.  Coronavirus disease 2019 (COVID-19): current status and future perspectives , 2020, International Journal of Antimicrobial Agents.

[30]  Olive Heffernan Why a landmark treaty to stop ocean biopiracy could stymie research , 2020, Nature.

[31]  David J Newman,et al.  Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. , 2020, Journal of natural products.

[32]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[33]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[34]  Justin J. J. van der Hooft,et al.  The Natural Products Atlas: An Open Access Knowledge Base for Microbial Natural Products Discovery , 2019, ACS central science.

[35]  Kelly N. Hassell Histone Deacetylases and Their Inhibitors in Cancer Epigenetics , 2019, Diseases.

[36]  L. Pilkington A Chemometric Analysis of Deep-Sea Natural Products , 2019, Molecules.

[37]  Young-Hoon Kang,et al.  Natural Products as Sources of Novel Drug Candidates for the Pharmacological Management of Osteoarthritis: A Narrative Review , 2019, Biomolecules & therapeutics.

[38]  Emma K Davison,et al.  Natural product derived privileged scaffolds in drug discovery. , 2019, Current opinion in chemical biology.

[39]  Joshua T. Horton,et al.  The future of force fields in computer-aided drug design. , 2019, Future medicinal chemistry.

[40]  Joseph D. Romano,et al.  Informatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives , 2019, Front. Genet..

[41]  Paromita Banerjee,et al.  Marine natural products as source of new drugs: a patent review (2015–2018) , 2019, Expert opinion on therapeutic patents.

[42]  Matthias Rarey,et al.  Conformator: A Novel Method for the Generation of Conformer Ensembles , 2019, J. Chem. Inf. Model..

[43]  F. Albericio,et al.  The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules , 2019, Molecules.

[44]  R. Shenvi,et al.  Natural Products in the "Marketplace": Interfacing Synthesis and Biology. , 2019, Journal of the American Chemical Society.

[45]  Asher Mullard 2018 FDA drug approvals , 2019, Nature Reviews Drug Discovery.

[46]  A. Najjar,et al.  The prodrug approach in the era of drug design , 2019, Expert opinion on drug delivery.

[47]  José L Medina-Franco,et al.  BIOFACQUIM: A Mexican Compound Database of Natural Products , 2018, Biomolecules.

[48]  The UniProt Consortium,et al.  UniProt: a worldwide hub of protein knowledge , 2018, Nucleic Acids Res..

[49]  David S. Goodsell,et al.  RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy , 2018, Nucleic Acids Res..

[50]  Jie Li,et al.  admetSAR 2.0: web‐service for prediction and optimization of chemical ADMET properties , 2018, Bioinform..

[51]  Nils-Ole Friedrich,et al.  Characterization of the Chemical Space of Known and Readily Obtainable Natural Products , 2018, J. Chem. Inf. Model..

[52]  W. Sippl,et al.  Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore. , 2018, Future medicinal chemistry.

[53]  J. Iqbal,et al.  Natural Product Inspired Topology Directed Synthesis of Hybrid Macrocyclic Compounds: A Simple Approach to Natural Product Analogues , 2018, ChemistrySelect.

[54]  Stuart L. Schreiber,et al.  Chemical probes and drug leads from advances in synthetic planning and methodology , 2018, Nature Reviews Drug Discovery.

[55]  W. Sippl,et al.  Identification of Bichalcones as Sirtuin Inhibitors by Virtual Screening and In Vitro Testing , 2018, Molecules.

[56]  F. Fratev,et al.  Prediction of Accurate Binding Modes Using Combination of Classical and Accelerated Molecular Dynamics and Free-Energy Perturbation Calculations: An Application to Toxicity Studies , 2018, bioRxiv.

[57]  Asher Mullard 2017 FDA drug approvals , 2018, Nature Reviews Drug Discovery.

[58]  Fidele Ntie-Kang,et al.  In silico toxicity profiling of natural product compound libraries from African flora with anti-malarial and anti-HIV properties , 2017, Comput. Biol. Chem..

[59]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[60]  Matthias Rarey,et al.  Benchmarking Commercial Conformer Ensemble Generators , 2017, J. Chem. Inf. Model..

[61]  Kai Blin,et al.  Recent development of computational resources for new antibiotics discovery. , 2017, Current opinion in microbiology.

[62]  J. Kirchmair,et al.  Data Resources for the Computer-Guided Discovery of Bioactive Natural Products , 2017, J. Chem. Inf. Model..

[63]  Adriano D. Andricopulo,et al.  NuBBEDB: an updated database to uncover chemical and biological information from Brazilian biodiversity , 2017, Scientific Reports.

[64]  M. Stiborová,et al.  Histone Deacetylase Inhibitors as Anticancer Drugs , 2017, International journal of molecular sciences.

[65]  Kiran K. Telukunta,et al.  NANPDB: A Resource for Natural Products from Northern African Sources. , 2017, Journal of natural products.

[66]  William H. Gerwick,et al.  Retrospective analysis of natural products provides insights for future discovery trends , 2017, Proceedings of the National Academy of Sciences.

[67]  Dominique Douguet,et al.  Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors , 2017, Scientific Reports.

[68]  A. Mai,et al.  Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. , 2017, Journal of medicinal chemistry.

[69]  Matthias Rarey,et al.  High-Quality Dataset of Protein-Bound Ligand Conformations and Its Application to Benchmarking Conformer Ensemble Generators , 2017, J. Chem. Inf. Model..

[70]  M. Diederich,et al.  Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer , 2016, Molecules.

[71]  Dianqing Sun,et al.  Privileged Scaffolds in Natural Products and Drug Discovery. , 2016, Current topics in medicinal chemistry.

[72]  P. J. Chilton,et al.  Use of traditional medicine in middle-income countries: a WHO-SAGE study , 2016, Health policy and planning.

[73]  D. Newman,et al.  Natural Products as Sources of New Drugs from 1981 to 2014. , 2016, Journal of natural products.

[74]  M. Kinch,et al.  An analysis of FDA-approved drugs: natural products and their derivatives. , 2016, Drug discovery today.

[75]  Inho Choi,et al.  Computer Aided Drug Design: Success and Limitations. , 2016, Current pharmaceutical design.

[76]  Stefan Günther,et al.  StreptomeDB 2.0—an extended resource of natural products produced by streptomycetes , 2015, Nucleic Acids Res..

[77]  Olivier Sperandio,et al.  iPPI-DB: an online database of modulators of protein–protein interactions , 2015, Nucleic Acids Res..

[78]  H. Suleria,et al.  Marine-Based Nutraceuticals: An Innovative Trend in the Food and Supplement Industries , 2015, Marine drugs.

[79]  F. Malerba,et al.  The evolution of the pharmaceutical industry , 2015 .

[80]  Herbert Waldmann,et al.  Stereoselective synthesis of a natural product inspired tetrahydroindolo[2,3-a]-quinolizine compound library. , 2015, Bioorganic & medicinal chemistry.

[81]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[82]  D. Dias,et al.  The pharmaceutical industry and natural products: historical status and new trends , 2015, Phytochemistry Reviews.

[83]  Chunmei Gao,et al.  Clustered Distribution of Natural Product Leads of Drugs in the Chemical Space as Influenced by the Privileged Target-Sites , 2015, Scientific Reports.

[84]  A. Harvey,et al.  The re-emergence of natural products for drug discovery in the genomics era , 2015, Nature Reviews Drug Discovery.

[85]  S. Kwon,et al.  Aceroside VIII is a New Natural Selective HDAC6 Inhibitor that Synergistically Enhances the Anticancer Activity of HDAC Inhibitor in HT29 Cells , 2015, Planta Medica.

[86]  Ly Le,et al.  Identification of Novel Compounds against an R294K Substitution of Influenza A (H7N9) Virus Using Ensemble Based Drug Virtual Screening , 2015, International journal of medical sciences.

[87]  Geoffrey A. Cordell,et al.  Phytochemistry and traditional medicine—The revolution continues , 2014 .

[88]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[89]  Herbert Waldmann,et al.  Biology-oriented synthesis: harnessing the power of evolution. , 2014, Journal of the American Chemical Society.

[90]  Wolfgang Sippl,et al.  Molecular Modeling of Potential Anticancer Agents from African Medicinal Plants , 2014, J. Chem. Inf. Model..

[91]  Hening Lin,et al.  Sirtuin inhibitors as anticancer agents. , 2014, Future medicinal chemistry.

[92]  C. Harrison Patenting natural products just got harder , 2014, Nature Biotechnology.

[93]  G. Burton,et al.  Emerging R and D law: the Nagoya Protocol and its implications for researchers. , 2014, ACS chemical biology.

[94]  Fidele Ntie-Kang,et al.  Virtualizing the p-ANAPL Library: A Step towards Drug Discovery from African Medicinal Plants , 2014, PloS one.

[95]  Ronald J Quinn,et al.  Natural products as lead structures: chemical transformations to create lead-like libraries. , 2014, Drug discovery today.

[96]  A. Hoelz,et al.  Structural and functional analysis of human SIRT1. , 2014, Journal of molecular biology.

[97]  B. Moore,et al.  Challenges and triumphs to genomics-based natural product discovery , 2014, Journal of Industrial Microbiology & Biotechnology.

[98]  Brian O. Bachmann,et al.  Microbial genome mining for accelerated natural products discovery: is a renaissance in the making? , 2014, Journal of Industrial Microbiology & Biotechnology.

[99]  Gerard D. Wright Something old, something new: revisiting natural products in antibiotic drug discovery. , 2014, Canadian journal of microbiology.

[100]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[101]  Wolfgang Sippl,et al.  AfroDb: A Select Highly Potent and Diverse Natural Product Library from African Medicinal Plants , 2013, PloS one.

[102]  F. Ntie‐Kang An in silico evaluation of the ADMET profile of the StreptomeDB database , 2013, SpringerPlus.

[103]  C. Busch,et al.  Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. , 2013, The Journal of nutritional biochemistry.

[104]  Lirong Chen,et al.  Use of Natural Products as Chemical Library for Drug Discovery and Network Pharmacology , 2013, PloS one.

[105]  F. Bucar,et al.  Natural product isolation--how to get from biological material to pure compounds. , 2013, Natural product reports.

[106]  C. Cruz-Hernandez,et al.  Bioavailability of bioactive food compounds: a challenging journey to bioefficacy. , 2013, British journal of clinical pharmacology.

[107]  Kunal Roy,et al.  How far can virtual screening take us in drug discovery? , 2013, Expert opinion on drug discovery.

[108]  Gajendra P. S. Raghava,et al.  NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database , 2012, Nucleic Acids Res..

[109]  J. Medina-Franco,et al.  Expanding the medicinally relevant chemical space with compound libraries. , 2012, Drug discovery today.

[110]  M. Zloh,et al.  Natural chalcones as dual inhibitors of HDACs and NF-κB , 2012, Oncology reports.

[111]  Stefan Wetzel,et al.  Charting, navigating, and populating natural product chemical space for drug discovery. , 2012, Journal of medicinal chemistry.

[112]  G. V. Paolini,et al.  Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.

[113]  Rohan A Davis,et al.  Drug-like properties: guiding principles for the design of natural product libraries. , 2012, Journal of natural products.

[114]  T. McKinsey Therapeutic potential for HDAC inhibitors in the heart. , 2012, Annual review of pharmacology and toxicology.

[115]  D. Christianson,et al.  Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. , 2011, Current opinion in structural biology.

[116]  Stefan Wetzel,et al.  Biology-oriented synthesis. , 2011, Angewandte Chemie.

[117]  Xiaohua Ma,et al.  Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting , 2011, Proceedings of the National Academy of Sciences.

[118]  G. Cordell,et al.  Sustainable Medicines and Global Health Care , 2011, Planta medica.

[119]  Supa Hannongbua,et al.  In-silico ADME models: a general assessment of their utility in drug discovery applications. , 2011, Current topics in medicinal chemistry.

[120]  Calvin Yu-Chian Chen,et al.  TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico , 2011, PloS one.

[121]  D. Sinclair,et al.  Mammalian sirtuins: biological insights and disease relevance. , 2010, Annual review of pathology.

[122]  Kuei-Meng Wu A New Classification of Prodrugs: Regulatory Perspectives , 2009, Pharmaceuticals.

[123]  Wei Lu,et al.  Do Biologically Relevant Compounds Have More Chance To Be Drugs? , 2009, J. Chem. Inf. Model..

[124]  Patrick E. McGovern,et al.  Ancient Egyptian herbal wines , 2009, Proceedings of the National Academy of Sciences.

[125]  Rajarshi Guha,et al.  Chemoinformatic Analysis of Combinatorial Libraries, Drugs, Natural Products, and Molecular Libraries Small Molecule Repository , 2009, J. Chem. Inf. Model..

[126]  H. Waldmann,et al.  Synthesis of natural product inspired compound collections. , 2009, Angewandte Chemie.

[127]  Tudor I. Oprea,et al.  Novel chemical space exploration via natural products. , 2009, Journal of medicinal chemistry.

[128]  Gisbert Schneider,et al.  Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.

[129]  G. Rishton,et al.  Natural products as a robust source of new drugs and drug leads: past successes and present day issues. , 2008, The American journal of cardiology.

[130]  Ruben Abagyan,et al.  Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.

[131]  H. Mewes,et al.  Can we estimate the accuracy of ADME-Tox predictions? , 2006, Drug discovery today.

[132]  Sorel Muresan,et al.  ChemGPS-NP: tuned for navigation in biologically relevant chemical space. , 2006, Journal of natural products.

[133]  A. Schuffenhauer,et al.  Charting biologically relevant chemical space: a structural classification of natural products (SCONP). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[134]  Ferenc Darvas,et al.  In Silico and Ex silico ADME approaches for drug discovery. , 2002, Current topics in medicinal chemistry.

[135]  M. Hesse Alkaloids: nature's curse or blessing? , 2002 .

[136]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[137]  John Hodgson,et al.  ADMET—turning chemicals into drugs , 2001, Nature Biotechnology.

[138]  Pravin Chaturvedi,et al.  Design principles for orally bioavailable drugs , 1996 .

[139]  H. Itazaki,et al.  Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. , 1990, The Journal of antibiotics.

[140]  R. Palmiter,et al.  Butyrate and related inhibitors of histone deacetylation block the induction of egg white genes by steroid hormones , 1980, Cell.

[141]  E. Groves A Dissertation ON , 1928 .

[142]  D. Kell,et al.  'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. , 2009, Drug discovery today.

[143]  B. van Wyk,et al.  A broad review of commercially important southern African medicinal plants. , 2008, Journal of ethnopharmacology.

[144]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[145]  D J Newman,et al.  The influence of natural products upon drug discovery. , 2000, Natural product reports.